期刊
JOURNAL OF LEUKOCYTE BIOLOGY
卷 102, 期 2, 页码 381-391出版社
WILEY
DOI: 10.1189/jlb.5VMR1016-449R
关键词
immunosuppression; MDSC; immunotherapy; oncology
资金
- Connor Family Foundation
- University of Colorado Cancer Center [P30CA046934]
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that represent a formidable obstacle to the successful treatment of cancer. Patients with high frequencies of MDSCs have significantly decreased progression-free survival (PFS) and overall survival (OS). Whereas there is experimental evidence that the reduction of the number and/or suppressive function of MDSCs in mice improves the efficacy of anti-cancer therapies, there is notably less evidence for this therapeutic strategy in human clinical trials. Here, we discuss currently available data concerning MDSCs from human clinical trials and explore the evidence that targeting MDSCs may improve the efficacy of cancer therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据